Multimodal Oncology Pipeline Targeting B7-H7- Positive Patients at Piper Sandler 36th Annual Healthcare Conference

2024 AACR LBx Poster-Determination of tumor PSMA expression and response Lutetium-PSMA in men with prostate cancer using a novel epigenomic liquid biopsy platform

Nextpoint Therapeutics to Participate in Stifel Healthcare Conference

Poster Presentation on a B7-H7 Directed T Cell Engager Therapy at SITC2024

Leerink Partners Biopharma Private Company Connect

Precede Biosciences Presents Data on Liquid Biopsy Comprehensive Epigenomic Profiling of MS Patients at ECTRIMS 2024

Poster- A Novel Comprehensive Epigenomic Liquid Biopsy Assay Reveals Disease Biology in Multiple Sclerosis Patients from 1mL of Plasma

Comprehensive Epigenomic Profiling from Plasma Inform Drug Development, Cancer Biology, and Therapy Selection

2024 ESMO Poster: Determination of tumor PSMA expression in prostate cancer from blood using a novel epigenomic liquid biopsy platform

Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging

First-in-class T Cell Engager NPX372 As New Drug Candidate Targeting B7-H7 in Solid Tumors

Predicta Biosciences Secures $5.2M to Transform the Diagnosis, Treatment and Monitoring of Blood Cancers

This Start-up Raised $5.2M to Develop Blood Tests for Cancer

Epigenomic signatures of sarcomaid differentiation guide treatment of renal cell carcinoma

Clinical Cancer Research: Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling

New Data At Asco 2024 Demonstrating Accurate Her2 Status Detection Across Multiple Cancers and The Ability To Quantify Er Pathway Activation In Breast Cancer From A Simple Blood Test